Patient and Provider Determinants Associated With the Prescription of Adjuvant Hormonal Therapies Following a Diagnosis of Breast Cancer in Medicaid-Enrolled Patients-Reference-Cited by-同舟云学术

Patient and Provider Determinants Associated With the Prescription of Adjuvant Hormonal Therapies Following a Diagnosis of Breast Cancer in Medicaid-Enrolled Patients

Published:2009-11 Issue:11 Volume:101 Page:1112-1118
ISSN:0027-9684
Container-title:Journal of the National Medical Association
language:en
Short-container-title:Journal of the National Medical Association

Author:

McLaughlin John M.,Balkrishnan Rajesh,Paskett Electra D.,Kimmick Gretchen G.,Anderson Roger T.

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers;Nadji;Am J Clin Pathol,2005

2. Fulvestrant—a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer;Possinger;Expert Opin Pharmacother,2004

3. Appraising adjuvant aromatase inhibitor therapy;Perez;Oncologist,2006

4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial;Baum;Lancet,2002

5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011;Breast Cancer Research and Treatment;2018-03-13

2. A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report of the ISPOR Oncology Good Outcomes Research Practices Working Group;Value in Health;2013-06